Big change in Sun Pharma's management, Kirti Ganorkar will be new…, billionaire Dilip Sanghvi will now have to..
Big change in Sun Pharma's management, Kirti Ganorkar will be new..., billionaire Dilip Sanghvi will now have to..
The top management of Sun Pharmaceutical Industries is going to see a lot of changes. The company has appointed Kirti Ganorkar as the new managing director. He will take over this responsibility from September 1, 2025, replacing Dilip Sanghvi. The pharmaceutical company said in a statement that the entire business and all functions will work under the supervision of Ganorkar. At the same time, Dilip Sanghvi will continue to chair the company's board as executive chairman.
Ganorkar's appointment as MD is subject to shareholder approval at Sun Pharma's upcoming annual general meeting. Ganorkar has been leading the India business at Sun Pharma since June 2019. Under his leadership, the company's India business has grown steadily, further increasing its market share. Prior to this, Ganorkar has held several leadership roles in the company across business development, marketing, mergers and acquisitions, new product introductions, project management, IP and litigation.
According to Sun Pharma, Ganorkar has played a key role in the company's entry into the specialty sector by acquiring rights to innovative products like Ilumya. He led the company's entry into Japan and laid the initial base for its entry into Europe. Ganorkar, who holds a degree in chemical engineering and an MBA, joined Sun Pharma in 1996. He also supported the US business along with steering several large generic projects from concept to commercialization. The company said Sanghvi will focus on strengthening the company's specialty portfolio.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
13 hours ago
- Time of India
Kirti Ganorkar: Why the veteran insider is the right dose for Sun Pharma
Mumbai: For nearly thirty years, Kirti Ganorkar quietly stood at Sun Pharma as a rock, much like his astute boss Dilip Shanghvi , the founder of Sun Pharma. Steadfastly Shanghvi steered Sun Pharma from a small India-focused branded generic player to one that is rapidly emerging as a global specialty drugs company. From September 1, Kirti Ganorkar (58), a chemical engineer and a diehard cricket aficionado, will helm India's largest drugmaker as its managing director, while Shanghvi will continue in the role of executive chairman. In a June 13 statement, Sun Pharma said this marks the culmination of a structured and forward-looking succession planning process, underscoring the organisation's commitment to leadership continuity and strategic governance. For Ganorkar's elevation, the timing is crucial given the global scale of Sun Pharma's operations. It includes a growing and challenging business environment in the US, Europe and a range of emerging markets while keeping Sun Pharma at the top of the intensely competitive home market, India. For FY2025, Sun Pharma had sales of ₹52,041 crore, a 9% growth over the previous year, while its net profit stood at ₹11,984 crore, up 19%. Of which, Sun Pharma's global specialty products sales stood at $1.21 billion (₹10,334 crore), up 17.1%, and accounted for 19.7% of FY25 sales. Alone, Sun Pharma's India sales contribute over 32% of its global revenues. When Ganorkar made his move from German Remedies (acquired later by Zydus Lifesciences in 2001), a united entity for a group of German pharma companies and joined Sun Pharma in 1996 as an executive assistant to Shanghvi, the Indian pharma market was very different. Sun Pharma was at a fraction of its present size. The market was poised for a leap in sales of drugs for heart ailments, diabetes, neurology, and cancer, the segments that have been the primary focus for the company. Now, the dynamics have changed with almost every large Indian company showing prowess of deep reach and scientific expertise as they try to outclass others from in-licensing innovative products to launching their own. Industry experts, who follow Sun Pharma closely, say Ganorkar has a tough task ahead, but the established strength of the company comes as a big help. To succeed Dilip Shanghvi, known for his calculated yet bold moves, Ganorkar will need to combine all his experience. He has held diverse roles at Sun Pharma from business development, marketing, M&A, new product introductions, project management, to intellectual property litigation. An avid cricket follower, Ganorkar is the perfect all-rounder that Shanghvi has chosen. In the new innings, he must demonstrate the skills of MS Dhoni as a cool captain while showing the aggression of Virat Kohli. "Can he be good in the test match format and T20. That is the key," says a senior industry veteran, who was pleasantly surprised to see Ganorkar's new position. Economic Times WhatsApp channel )
The Hindu
16 hours ago
- The Hindu
Sun Pharma's Halol facility issued eight observations by U.S. FDA
Sun Pharmaceutical Industries' drug manufacturing facility in Halol, Gujarat, has been issued eight observations by the U.S. Food and Drug Administration (FDA). The U.S. FDA issued a Form-483 with eight observations following conclusion of a Good Manufacturing Practices (GMP) inspection of the facility from June 2-13, Sun Pharma said in a filing to the stock exchanges on Saturday. 'This is further to our update on Halol dated 16 December 2022,' the company said, referring to the warning letter the U.S. FDA had issued to the facility. The warning letter came close on the heels of regulator placing the Halol facility under import alert. The warning letter had summarised violations with respect to current good manufacturing practice (cGMP) regulations.
United News of India
20 hours ago
- United News of India
Sun Pharma appoints Kirti Ganorkar as new MD
Mumbai, June 14 (UNI) Pharma major Sun Pharmaceutical Industries said that it has appointed Kirti Ganorkar as the Managing Director of the company effective September 1, 2025, succeeding Dilip Shanghvi to the job. The entire business and all functions will be reporting to Ganorkar. This appointment is subject to approval of the shareholders at the upcoming annual general meeting, the company release said. The announcement marks the culmination of a structured and forward-looking succession planning process at Sun Pharma, underscoring the organisation's commitment to leadership continuity and strategic governance. Ganorkar has been heading India Business at Sun Pharma since June 2019. Under his leadership, the company's India Business has grown consistently, further increasing its market share. Previously, he has held various leadership roles across business development, marketing, M&A, new product introduction, project management, IP and litigation at the drug firm, it added. Ganorkar played a key role in driving Sun Pharma's foray into speciality by securing rights for innovative products such as Ilumya. He led the company's entry into Japan and laid the initial groundwork for the company's foray into Europe, it said. Ganorkar also supported the US business with stewardship of several notable generic projects from concept to commercialisation. As Executive Chairman, Shanghvi will continue to chair the Board. He will focus on strengthening Sun Pharma's speciality portfolio and provide insights towards shaping the company's long-term strategy, the release added. Dilip Shanghvi, Chairman & Managing Director of Sun Pharma, said, ''Kirti has consistently demonstrated effective leadership, managing diverse roles at Sun. "I have a firm belief in his ability to lead the company into its next phase of growth and extend my best wishes for his success." His elevation showcases our strong in-house talent pool, ensuring continuity of Sun Pharma's core value systems." UNI JS ARN
